ClinicalTrials.gg
RecruitingNCT07242391Updated Aug 27, 2026

Menopausal Hormone Therapy And Left Ventricular Function

An observational study in Menopause and Left Ventricular Dysfunction, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to female participants aged 45 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Mayo Clinic · Observational

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
50
Ages
45 Years to 60 Years
Sex
Female
01

Study summary

The purpose of this study is to compare left ventricular stroke volume and heart rate responses to bursts of SNA between PMF using, and not using, MHT.

02

Conditions studied

  • Menopause
  • Left Ventricular Dysfunction
03

In context

Ventricular Dysfunction, Left

260 studies on the registry are indexed under Ventricular Dysfunction, Left; 57 are open to participants now.

This study's planned enrollment of 50 is below the median of 198 across 103 observational studies indexed under Ventricular Dysfunction, Left.

Browse Ventricular Dysfunction, Left studies →

Lead sponsor

Mayo Clinic is the lead sponsor of 3,269 studies on the registry; 672 are open to participants now.

Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 60 Years
Sexes eligible
Female
Sampling method
Non-probability sample

Study population

Study participants will be recruited from various Mayo Clinic departments/clinics located at Rochester and surrounding communities.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >45-60\< years of age

Exclusion criteria

Exclusion Criteria

  • Male sex
  • Females between STRAW+10 stages -5 and 0
  • PMF in STRAW+10 stage +2
  • PMF using oral hormone therapy
  • Females who entered menopause due to a surgical procedure or in response to pharmacotherapy (e.g., gonadotrophin releasing hormone agonists or chemotherapy)
  • Heart disease such as hypertropic cardiomyopathy, congenital abnormalities, chronic heart failure, valve disease, and a history of myocardial infarction
  • Medications that impact the central nervous system including selective serotonin reuptake inhibitors, anxiolytics, sedatives, anticholinergic agents, dopamine, amphetamines, or wake-promoting agents (e.g., modafinil). Other medications will be evaluated on an individual basis by the PI.
  • Cardiovascular medications is also an exclusion criterion which includes those acting on the renin-angiotensin-aldosterone axis, adrenergic receptor antagonists, diuretics, nitrates, and calcium channel antagonists. Other medications will be evaluated on an individual basis by the PI.
  • Pregnancy
  • Diabetes
  • CKD
  • Raynaud's phenomenon
  • Sleep disorders
  • Shift workers
  • ≥40.0kg/m2
  • Use of nicotine-containing products within the two years preceding study visits
  • Active cancer treatment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Post-menopausal females using menopausal hormone therapy

    Post menopausal females taking a clinically prescribed menopausal hormone therapy (i.e. pill, patch, etc.)

    Drug: Menopausal Hormone Therapy

  • Post-menopausal females not using menopausal hormone therapy

Interventions

  • DrugMenopausal Hormone Therapy

    Taken in accordance with standard clinical practice, administered for a minimum duration of eight weeks.

06

What researchers measure

Primary outcomes

  1. Left ventricular stroke volume

    Left ventricular stroke volume is the amount of blood pumped from the left ventricle per heartbeat (mL)

    Time frame: Baseline

Secondary outcomes

  1. Ventriculo-Arterial (VA) coupling

    Ventriculo-Arterial (VA) coupling will be measured as the ratio of end-systolic elastance (Ees) to arterial elastance (Ea).

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2025
First posted
Nov 21, 2025
StartActual
Aug 26, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07242391
Lead sponsor
Mayo Clinic
Responsible party
Joshua M. Bock (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Nov 21, 2025
Start date
Aug 26, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 27, 2026

Study contacts

Joshua Bock, Ph.D.
Contact
bock.joshua@mayo.edu
507-422-0768
Joshua Bock, Ph.D.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion